ArticleBioengineering & translational medicine2021
Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer.
Article in Bioengineering & translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Localized delivery of hyaluronic acid-doxorubicin from a surgical paste for post-operative glioblastoma treatment.Materials today. Bio · 2026Article
- In Silico Identification of Hydroxyxanthone Derivatives as CDK2/EGFR Dual Inhibitor for Colorectal Cancer Treatment.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Low-dose DOX-polygodial nanosystem modulates the CD47/CALR axis for safer triple negative breast cancer treatment.Nanoscale advances · 2026Article
- Recent advances in nanomaterial-based precision medicine for orthotopic tumor therapy.Journal of nanobiotechnology · 2026Review
- Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Identifying Molecular Modulators of the Vascular Invasion in Rectal Carcinoma: Role ofInternational journal of molecular sciences · 2025Article
- TMOD2 and DOCK4 as Novel Gut Microbiota-Associated Biomarkers for Colorectal Adenoma: Integrated Transcriptomic Analysis and Therapeutic Target Identification.Mediators of inflammation · 2025Article
- Article
- Glycosaminoglycans' Ability to Promote Wound Healing: From Native Living Macromolecules to Artificial Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade.Journal of experimental & clinical cancer research : CR · 2024Article
- Synergistic ferroptosis-starvation therapy for bladder cancer based on hyaluronic acid modified metal-organic frameworks.Bioengineering & translational medicine · 2023Article
- Nano-Drug Delivery Systems Based on Different Targeting Mechanisms in the Targeted Therapy of Colorectal Cancer.Molecules (Basel, Switzerland) · 2022Review
- Synthesis of Polyethylene Glycol Diacrylate/Acrylic Acid Nanoparticles as Nanocarriers for the Controlled Delivery of Doxorubicin to Colorectal Cancer Cells.Pharmaceutics · 2022Article
- Design of Bio-Responsive Hyaluronic Acid-Doxorubicin Conjugates for the Local Treatment of Glioblastoma.Pharmaceutics · 2022Article
- Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma.Frontiers in cell and developmental biology · 2022Article
- Folic Acid-Decorated pH-Responsive Nanoniosomes With Enhanced Endocytosis for Breast Cancer Therapy:Frontiers in pharmacology · 2022Article
- Targeting pathophysiological changes using biomaterials-based drug delivery systems: A key to managing inflammatory bowel disease.Frontiers in pharmacology · 2022Review
- Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients.Materials (Basel, Switzerland) · 2021Review
- Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer.Bioengineering & translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Colorectal cancer, common in both men and women, occurs when tumors form in the linings of the colon. Common treatments of colorectal cancer include surgery, chemotherapy, and radiation therapy; however, many colorectal cancer treatments often damage healthy tissues and cells, inducing severe side effects. Conventional chemotherapeutic agents such as doxorubicin (Dox) can be potentially used for the treatment of colorectal cancer; however, they suffer from limited targeting and lack of selectivity. Here, we report that doxorubicin complexed to hyaluronic acid (HA) (HA-Dox) exhibits an unusual behavior of high accumulation in the intestines for at least 24 hr when injected intravenously. Intravenous administrations of HA-Dox effectively preserved the mucosal epithelial intestinal integrity in a chemical induced colon cancer model in mice. Moreover, treatment with HA-Dox decreased the expression of intestinal apoptotic and inflammatory markers. The results suggest that HA-Dox could effectively inhibit the development of colorectal cancer in a safe manner, which potentially be used a promising therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.